Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer.
Animals
Antigens, Neoplasm
/ immunology
Cell Adhesion Molecules
/ antagonists & inhibitors
Cell Line, Tumor
Cell Membrane
/ metabolism
Cell Movement
/ immunology
Female
Immunoconjugates
/ immunology
Membrane Proteins
/ metabolism
Mice
Models, Animal
Ovarian Neoplasms
/ metabolism
Positron-Emission Tomography
/ methods
Radioisotopes
/ chemistry
Surface Plasmon Resonance
/ methods
Transplantation, Heterologous
/ methods
Zirconium
/ chemistry
src-Family Kinases
/ metabolism
CDCP1
antibody
immuno-conjugate
ovarian cancer
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
10
2018
accepted:
13
12
2019
entrez:
28
2
2020
pubmed:
28
2
2020
medline:
15
4
2021
Statut:
epublish
Résumé
CUB-domain containing protein 1 (CDCP1) is a cancer associated cell surface protein that amplifies pro-tumorigenic signalling by other receptors including EGFR and HER2. Its potential as a cancer target is supported by studies showing that anti-CDCP1 antibodies inhibit cell migration and survival
Identifiants
pubmed: 32104500
doi: 10.7150/thno.30736
pii: thnov10p2095
pmc: PMC7019151
doi:
Substances chimiques
Antigens, Neoplasm
0
CDCP1 protein, mouse
0
Cell Adhesion Molecules
0
Immunoconjugates
0
Membrane Proteins
0
Radioisotopes
0
Zirconium
C6V6S92N3C
src-Family Kinases
EC 2.7.10.2
Zirconium-89
NTM296JU95
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2095-2114Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: The authors have declared that no competing interest exists.
Références
Cell. 2005 Apr 22;121(2):271-80
pubmed: 15851033
Clin Cancer Res. 2004 Oct 15;10(20):7063-70
pubmed: 15501986
Br J Cancer. 2016 Feb 16;114(4):417-26
pubmed: 26882065
Breast Cancer Res. 2016 Aug 05;18(1):80
pubmed: 27495374
Cancer Sci. 2011 Nov;102(11):1943-8
pubmed: 21812858
Gastroenterology. 2010 Jul;139(1):292-303
pubmed: 20303350
Pharm Res. 2015 Nov;32(11):3470-9
pubmed: 25446773
Elife. 2018 Jan 23;7:
pubmed: 29359686
PLoS One. 2015 Apr 13;10(4):e0123472
pubmed: 25876044
Mol Oncol. 2013 Dec;7(6):1142-51
pubmed: 24055141
J Biol Chem. 2014 May 30;289(22):15384-92
pubmed: 24737329
Nat Cell Biol. 2011 Mar;13(3):331-7
pubmed: 21297641
Cancer Immunol Immunother. 2008 Dec;57(12):1879-90
pubmed: 18408925
J Pharm Biomed Anal. 2017 May 30;139:65-72
pubmed: 28279929
J Biol Chem. 2012 Mar 23;287(13):9792-9803
pubmed: 22315226
Cell Rep. 2017 Jun 6;19(10):2102-2115
pubmed: 28591581
Am J Pathol. 2008 Jun;172(6):1729-39
pubmed: 18467693
Cancer Res. 2011 Mar 15;71(6):2250-9
pubmed: 21406401
Br J Cancer. 2004 Sep 13;91(6):1200-4
pubmed: 15305184
Oncogene. 2018 May;37(21):2817-2836
pubmed: 29511352
Nat Cell Biol. 2014 Jun;16(6):561-73
pubmed: 24859005
Br J Dermatol. 2013 Mar;168(3):496-503
pubmed: 23121233
Cancer Res. 2010 Jun 15;70(12):5136-46
pubmed: 20501830
Mol Pharm. 2010 Feb 1;7(1):245-53
pubmed: 19916495
Oncogene. 2012 Aug 30;31(35):3924-38
pubmed: 22179830
Nat Rev Mol Cell Biol. 2002 Aug;3(8):600-14
pubmed: 12154371
Oncogene. 2015 Mar 12;34(11):1375-83
pubmed: 24681947
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1379-84
pubmed: 21220330
Theranostics. 2017 Sep 20;7(17):4071-4086
pubmed: 29158811
Cancer Sci. 2017 May;108(5):1049-1057
pubmed: 28256037
Biol Chem. 2018 Sep 25;399(9):1091-1097
pubmed: 29447112
Gastroenterology. 2013 Sep;145(3):636-46.e5
pubmed: 23747337
Oncotarget. 2017 Jul 4;8(27):44605-44624
pubmed: 28574834
Mol Cell Proteomics. 2013 Jan;12(1):180-93
pubmed: 23105007
Biochim Biophys Acta. 2008 Mar;1780(3):486-96
pubmed: 18269919
Oncogene. 2014 Jan 9;33(2):255-68
pubmed: 23208492
Clin Cancer Res. 2009 Apr 1;15(7):2311-22
pubmed: 19318475
Oncogene. 2016 Jan 28;35(4):468-78
pubmed: 25893298
Oncotarget. 2016 Oct 25;7(43):69649-69665
pubmed: 27626701
Cancer Res. 2008 May 15;68(10):3759-66
pubmed: 18483259
Blood. 2011 Aug 25;118(8):2211-21
pubmed: 21730355
J Biol Chem. 2011 Dec 9;286(49):42303-42315
pubmed: 21994943
Mol Cancer. 2015 Jul 31;14:147
pubmed: 26227951
Methods Mol Biol. 2013;1045:285-93
pubmed: 23913155
Cell Rep. 2015 Apr 28;11(4):564-76
pubmed: 25892239
Int J Mol Sci. 2016 Nov 08;17(11):
pubmed: 27834817
Oncogene. 2016 Sep 8;35(36):4762-72
pubmed: 26876198
Am J Pathol. 2009 May;174(5):1756-65
pubmed: 19349359
Theranostics. 2019 Sep 19;9(22):6706-6718
pubmed: 31588245
Mol Cancer Res. 2009 Aug;7(8):1197-211
pubmed: 19671673
Oncogene. 2003 Mar 27;22(12):1783-94
pubmed: 12660814
J Immunol Methods. 2016 Apr;431:11-21
pubmed: 26851520
J Vis Exp. 2015 Feb 12;(96):
pubmed: 25741890
PLoS One. 2014 Mar 19;9(3):e92444
pubmed: 24647355
IUBMB Life. 2009 Jul;61(7):723-30
pubmed: 19514048
Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):1931-6
pubmed: 21233420
Clin Cancer Res. 2014 Mar 1;20(5):1288-97
pubmed: 24398046
J Biol Chem. 2010 Aug 20;285(34):26162-73
pubmed: 20551327
Breast Cancer Res Treat. 2015 Aug;153(1):123-33
pubmed: 26253944
Cytotechnology. 2013 Oct;65(5):795-802
pubmed: 23440375
Cancer Sci. 2013 Jul;104(7):865-70
pubmed: 23510015
Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):3483-8
pubmed: 23378636
Mol Cell Biol. 2007 Nov;27(21):7649-60
pubmed: 17785447
Cold Spring Harb Protoc. 2016 Aug 01;2016(8):
pubmed: 27480717
J Biol Chem. 2004 Apr 9;279(15):14772-83
pubmed: 14739293